Graviton BioScience Corp
StreetZero Signal 74
About Graviton BioScience Corp
Graviton Bioscience is a privately held clinical-stage biotechnology company focused on therapies that inhibit Rho/Rho-associated coiled-coil containing protein kinase 2 (ROCK2). The company is advancing the clinical development of GV101 and its pipeline of ROCK2 inhibitors to treat serious fibrotic, inflammatory, and neurologic conditions. It operates as a B2B business in the biotechnology research industry and is headquartered in New York, New York.
LATEST FUNDINGPrivate Placement
$5.0M
Announced 2026-11-16
TOTAL RAISED$64.82M
IN THE NEWS
- ๐ Graviton Bioscience Receives Financing From Enavate Sciences
- ๐ Graviton BioScience
- ๐ Graviton BioScience 2026 Company Profile: Valuation, Funding & Investors | PitchBook
- ๐ Graviton Bioscience - 2026 Company Profile, Funding & Competitors - Tracxn
- ๐ Graviton Bioscience - 2026 Company Profile, Funding & Competitors - Tracxn
EMPLOYEESโ
FOUNDED2023
HQNew York, NY, United States
Industry
Biotechnology
Tags
BiotechnologyClinical-stageROCK2 inhibitorsB2B
Investors
Key highlights
- Completed financing from Enavate Sciences to advance GV101 and ROCK2 inhibitor pipeline.
- Total funding reached $64.82M across venture and private equity rounds.
- Focuses on treatments for fibrotic, inflammatory, and neurologic conditions with no current cures.
- Backed by investors including Patient Square Capital portfolio company and Sanofi.
Ask StreetZero about Graviton BioScience Corp
Put our AI to work on this deal.
Similar companies
Other Biotechnology deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account